Search clinical trials for: Tislelizumab with Fruquintinib, Metronidazole

Total 101 results

Jing-yuan Fang, MD, Ph. D

Recruiting

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

Colorectal Cancer

China
Huazhong University of Science and Technology

Active, not recruiting

Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC

Patients With Advanced Metastatic Colorectal Cancer

China
Peking University Cancer Hospital & Institute

Not yet recruiting

Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer (PKUCH-R09)

Rectal Cancer

China
Sun Yat-sen University
Hutchmed; BeiGene

Not yet recruiting

Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

Metastatic Colorectal Cancer | mCRC

China
Fudan University

Recruiting

The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)

Metastatic Colorectal Cancer

China
Sun Yat-sen University

Not yet recruiting

Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score

Locally Advanced Rectal Cancer

China
Hutchmed

Recruiting

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Advanced Solid Tumor

China
Fudan University

Recruiting

Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

HER2-positive Gastric Cancer | Immunotherapy

China
Hutchison Medipharma Limited

Completed

Fruquintinib Food Effect and Proton Pump Inhibitor Study

Food-drug Interaction | Drug Interaction

United States
Fujian Cancer Hospital

Not yet recruiting

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases

Colo-rectal Cancer
Fudan University

Recruiting

Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Colorectal Cancer | Refractory Colorectal Carcinoma

China
RenJi Hospital
Shanghai Zhongshan Hospital

Not yet recruiting

Fruquintinib and Serplulimab Combination Therapy for First-line Treatment of Non-clear Cell Renal Cell Carcinoma: A Prospective Multicenter Study

First-line Treatment of Non-clear Renal Cell Carcinoma
Peking Union Medical College Hospital

Recruiting

A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
BeiGene
Hutchison Medipharma Limited

Completed

Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

Advanced Solid Tumors

Korea, Republic of, China
Jiangsu Yahong Meditech Co., Ltd aka Asieris

Recruiting

A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (ANTICIPATE)

Muscle Invasive Bladder Cancer

United States, China
Henan Cancer Hospital

Recruiting

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

Metastatic Gastroesophageal Junction Adenocarcinoma

China
Sun Yat-sen University

Recruiting

Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Bladder Cancer Stage IV

China
XIANG YANQUN

Recruiting

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

Nasopharyngeal Carcinoma

China
Hutchison Medipharma Limited
BeiGene

Active, not recruiting

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Colorectal Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Solid Tumor, Unspecified, Adult

United States
Fudan University

Recruiting

Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Recruiting

Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC (TALENT)

Recurrent Hepatocellular Carcinoma

China
Second Affiliated Hospital of Nanchang University

Recruiting

Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma

Immunotherapy | Tislelizumab | Pulmonary Pleomorphic Carcinoma

China
Wuhan Union Hospital, China

Recruiting

The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

Breast Cancer | Neoadjuvant Therapy

China
Fudan University

Not yet recruiting

Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients

Colorectal Cancer | Microsatellite Stable Colorectal Carcinoma

China
Peking University

Recruiting

Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment

Liver Metastasis Colon Cancer | MSS | ctDNA Genotype | Failed From Standard Treatment

China
Zhou Fuxiang
Xiangya Hospital of Central South University; Henan Cancer Hospital; Hubei Cancer... and other collaborators

Recruiting

Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
RenJi Hospital

Recruiting

Combination of RC48 and Tislelizumab for Renal Preservation in High-risk UTUC Patients

Upper Urinary Tract Urothelial Carcinoma | Kidney Preservation | HER-2 ADC | PD-1antibody

China
First Affiliated Hospital of Guangxi Medical University

Recruiting

The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer

Rectal Cancer | Rectal Cancer Stage II | Rectal Cancer Stage III

China
Ruijin Hospital

Not yet recruiting

Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer

Non-muscle-invasive Bladder Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer (NEXUS-2)

Esophagus Cancer

China
Translational Research in Oncology
Bayer; Novartis

Withdrawn

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers (REFIT-MSS)

Soft Tissue Sarcoma | Small Cell Lung Carcinoma | Colorectal Neoplasms | Anal Squamous Cell Carcinoma | Malignant Pleural Mesothelioma | Castrate Resistant Prostate Cancer | Gastroenteropancreatic Neuroendocrine Neoplasm | Neuroendocrine Carcinoma of Prostate
Ningbo No. 1 Hospital
Zhejiang University

Recruiting

CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

Diffuse Large B-cell Lymphoma

China
Xiaofeng Chen

Recruiting

XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Evaluation of The Efficacy And Safety of PD-1 + IL-2 Combined With Capox Treatment After Loop Colostomy Surgery in Left-sided Colorectal Cancer Patients Complicating Acute Obstruction

Left-sided Colorectal Cancer Complicating Acute Obstruction
The First Affiliated Hospital of Xinxiang Medical...
BeiGene

Not yet recruiting

Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell Carcinoma

ESCC
Immix Biopharma, Inc.
Novartis; BeiGene

Recruiting

Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors (IMMINENT-01)

Advanced Solid Tumor

Brazil
Zhejiang Cancer Hospital

Not yet recruiting

Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer

Advanced Colorectal Cancer

China
First Affiliated Hospital of Guangxi Medical University

Recruiting

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Cervical Cancer

China
Tillotts Pharma AG
University Hospital, Basel, Switzerland; University of Basel; SocraTec R&D GmbH; Swiss Commission for Technology and Innovation

Completed

Pharmaco-Scintigraphic Study to Evaluate the Release Profile of Metronidazole Benzoate Capsules

Healthy

Switzerland
Duke University

Completed

Perioperative Tissue Penetration of Antimicrobials in Infants

Bowel Dysfunction

United States
Zhongda Hospital

Recruiting

Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase Ib/II Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma

Bladder Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Zhongnan Hospital
Hubei Cancer Hospital; Sir Run Run Shaw Hospital; Huangshi Central Hospital,... and other collaborators

Active, not recruiting

Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression (HCCSC-C03)

Colorectal Cancer | HER2

China
Zhejiang Cancer Hospital

Recruiting

GOT Applied as Neoadjuvant Regimen for Patients of Resectable ICC With High-risk Factors of Recurrence (GOT)

Intrahepatic Cholangiocarcinoma

China
Xijing Hospital

Recruiting

Tislelizumab Combined With XELOX as Neoadjuvant Therapy for G/GEJ Adenocarcinoma

Locally Advanced Gastric Adenocarcinoma

China
Zealand University Hospital
Region Zealand; Costerton Biofilm Center; Reponex Pharmaceuticals A/S

Completed

Preoperative Endoscopic Treatment With Fosfomycin and Metronidazole in Patients With Right-sided Colon Cancer and Colon Adenoma (MEFO-trial) (MEFO)

Right-sided Colon Cancer | Right-sided Colon Adenoma

Denmark
National Cancer Centre, Singapore
Tan Tock Seng Hospital; BeiGene

Not yet recruiting

Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Singapore
The Catholic University of Korea
St Vincent's Hospital; Bucheon St. Mary's Hospital

Unknown

Concomitant Therapy of H. Pylori

Gastritis, Gastric Ulcer, and Duodenal Ulcer

Korea, Republic of
Second Affiliated Hospital, School of Medicine,...

Recruiting

Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status

Colorectal Cancer | Liver Metastases

China

3

Subscribe